Protocols

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

Geoffrey Porges, Leerink

Geoffrey Porges, Leerink

Count Geoffrey Porges in the mix of analysts cheering Ionis $IONS and Biogen $BIIB forward on fresh evidence of the efficacy of nusinersen for spinal muscular atrophy. In a note today the Leerink analyst said that after investigators release more data over the weekend, he views an approval for Type 1 SMA as a “near certainty.” And there’s some evidence to suggest that the upside could be significantly broadened with approvals for Type II and Type III SMA as well. That is encouraging enough for Porges to boost his peak 2025 sales estimate to $2.5 billion, 20% to 30% ahead of consensus. Both companies badly need a win here.

Daiichi Sankyo has signed up to partner with a team of Dana-Farber investigators led by Pasi Janne on a preclinical translational med effort. No terms were disclosed. Janne was also listed as a principal investigator on one of the olmutinib trials sponsored by Hanmi and Boehringer ingelheim, now the subject of a controversy in South Korea.

France’s Transgene is sponsoring a Phase I/II study matching its immunotherapy TG4001 with Merck KGaA’s PD-L1 checkpoint drug avelumab.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

EvaluatePharma World Preview 2017